Aspiring to be the Google Maps of the cell, Apricot Therapeutics, a spin-off from University of Zürich, is commercialising 4i imaging technology based on 17 years of development conducted at Pelkmans Lab, ETH Zürich and University of Zurich. Exclusivity on 2 patents for imaging + learning algorithms
Products, services, technology
Service delivers multiplex drug response profiling of patient biopsies at subcellular, single-cell, and multicellular scales, enabling high spatial resolution across large areas, no need for conjugated antibodies, identifies non-responders that typically make trials fail, unprecedented scalability
Cooperation possibilities
Drug discovery companies: to accelerate lead compound characterisation (e.g. Molecular Glue Degraders)
Hospitals/healthcare providers: for drug response profiling of ex vivo patient biopsies to improve treatment outcomes
Large pharma: to accelerate drug development (pre/clinical stages)
- http://www.Apricotx.com
- +41 44 63 53 123
- Info@Apricotx.com
- Michael Zering
Some insights
AI may revolutionize drug discovery/ healthcare, but the necessary data are still largely missing because the fundamental nature of how living systems work dictates that the action of any intervention is highly context-dependent across multiple spatiotemporal scales. APx bridges the gap
We are proud of the opportunity to commercialise 17 years of technology innovation developed at Pelkmans Lab, University of Zürich. The technology fills a gap in existing (-omics) data technologies and collects it at scale enabling trained AI algorithms to achieve unprecedented predictability
APx is fortunate to have highly skilled colleagues that transitioned from PhD studies in life sciences and systems biology at Pelkmans Lab over to the start-up. Deep knowledge of the 4i platform is achieved, underpinned with a diverse leadership team (entrepreneurial + big-4 consulting)
At work? My children would say I spend too much time typing and talking and not enough time skiing
Senior leaders at Tier 1 Pharma companies focused on drug discovery, reducing R&D costs for large scale projects.
SME Biotechs developing molecules (e.g. molecular glue degraders)
World class labs needing a platform that will connect the dots for precision medicine